A modified Rim APHE criterion to improve LI-RADS diagnostic performance for primary liver malignancies
Abdominal Radiology · 2026
DOI: 10.1007/s00261-026-05551-9 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Chunying Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Yangfangdian Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Friendship Hospital Seed Project of Capital Medical University, Beijing Hospitals Authority Clinical medicine Development of special funding.
Abstract (Originalsprache)
PURPOSE: To refine the diagnostic criteria for rim arterial phase hyperenhancement (Rim APHE) and to evaluate the impact of this modification on the diagnostic performance for primary liver malignancies. MATERIALS AND METHODS: This multicenter, retrospective study included patients with pathologically confirmed primary liver malignancies who underwent preoperative magnetic resonance imaging (MRI) before June 2021. Thirteen different measurement methods for Rim APHE were evaluated to determine the optimal criterion based on diagnostic performance. Two radiologists independently reviewed all observations, assigned Liver Imaging Reporting and Data System (LI-RADS) categories according to version 2018. The diagnostic performance of LI-RADS using original versus modified Rim APHE criteria was compared. RESULTS: The study enrolled 272 patients, including 204 with Hepatocellular carcinoma (HCC) (170 men and 34 women; mean age, 57 years ±10) and 68 with non-HCC malignancies (53 men and 15 women; mean age, 56 years ±10). The optimal criterion for Rim APHE was the total thickness of the thickest part of peripheral hyperenhancement to tumor diameter (area under the receiver operating characteristic (ROC) curve [AUC] = 0.852; P < .001). With implementation of the modified Rim APHE criterion, the LR-5 criteria showed significantly superior AUC (0.770 vs. 0.752, p = .007), sensitivity (76.0% vs. 72.5%, p = .016) and accuracy (76.5% vs. 73.9%, p = .016); the LR-M criteria showed higher AUC (0.831 vs. 0.811, p = .004), specificity (92.7% vs. 88.7%, p = .008) and accuracy (87.9% vs. 84.9%, p = .008). CONCLUSION: The optimal criterion for Rim APHE can improve the diagnostic performance for both HCC and non-HCC malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Yangfangdian Hospital, Beijing, China.
- Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Dongfang Hospital, Beijing University of Chinese medicine, Beijing, China.
- The Second Xiangya Hospital of Central South University, Changsha, China.
- The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Förderung
- National Natural Science Foundation of China
- Beijing Friendship Hospital Seed Project of Capital Medical University
- Beijing Hospitals Authority Clinical medicine Development of special funding
Zitieren
APA
Feng, C., Liu, J., Yang, D., Xu, L., Li, M., Bao, Y., Dong, J., Luo, J., Chen, Q., Liao, R., Li, C., Wang, R., Xu, H., & Yang, Z. (2026). A modified Rim APHE criterion to improve LI-RADS diagnostic performance for primary liver malignancies. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05551-9
Vancouver
Feng C, Liu J, Yang D, Xu L, Li M, Bao Y, et al. A modified Rim APHE criterion to improve LI-RADS diagnostic performance for primary liver malignancies. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05551-9
BibTeX
@article{Feng2026,
author = {Feng, Chunying and Liu, Jun and Yang, Dawei and Xu, Lixue and Li, Min and Bao, Yan and Dong, Jinghui and Luo, Jiawen and Chen, Qingqing and Liao, Rufang and Li, Chenxia and Wang, Rongpin and Xu, Hui and Yang, Zhenghan},
title = {A modified Rim APHE criterion to improve LI-RADS diagnostic performance for primary liver malignancies},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05551-9}
}
EUVIMED